CN Patent

CN106559991A — 用于激酶抑制的杂芳基化合物

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2017-04-05 · 9y expired

What this patent protects

本文描述调节包括突变EGFR和突变HER2激酶活性的激酶活性的化合物和药物组合物、以及治疗与包括突变EGFR和突变HER2活性的激酶活性相关的疾病和病状的化合物、药物组合物和方法。

USPTO Abstract

本文描述调节包括突变EGFR和突变HER2激酶活性的激酶活性的化合物和药物组合物、以及治疗与包括突变EGFR和突变HER2活性的激酶活性相关的疾病和病状的化合物、药物组合物和方法。

Drugs covered by this patent

mobocertinib-succinate (MOBOCERTINIB SUCCINATE)

Patent Metadata

Patent number: CN106559991A
Jurisdiction: CN
Classification: —
Expires: 2017-04-05
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.